The global market for precision medicine is projected to top more than
$84.5 billion by 2024. Targeted therapies for rare, genetic diseases, cancer and chronic conditions come with the hope of a cure.
Companies such as
Roche,
Novartis,
Spark Therapeutics (now owned by Roche),
Pfizer,
Editas Medicine, and
BioMarin Pharmaceuticals are among the pharma players in this space. There seem to be new developments in precision medicine on
almost a weekly basis.
So what do educational institutions need to do to create fertile ground for gene therapy research to produce the next generation of companies developing these therapies? And what needs to happen to facilitate data sharing, ensure access to genome sequencing and these promising therapies?
A new eBook highlights compelling conversations around a couple of events that took place during the JP Morgan Healthcare conference in January this year. One, hosted by the Penn Center for Innovation, offers a showcase of the latest biotech innovations emerging from Penn and the Perelman School of Medicine. Another, hosted by Deloitte and
P4ML, drew attention to an initiative by the World Economic Forum to improve the way genomic data is shared to develop better treatments for rare diseases and ethical considerations for access to precision medicine.
Fill in the form below to download the eBook,
The Pathway to Precision Medicine.
Picture: Getty Images
